Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 7, 2013 - Issue
Submit an article Journal homepage
77
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a Phase II, randomized study

Konstantinos Zarogoulidis1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Eftimios Ziogas1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Efimia Boutsikou1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Paul Zarogoulidis1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece;2 Department of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital, University Duisburg-Essen, Essen, GermanyCorrespondence[email protected]
,
Kaid Darwiche2 Department of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital, University Duisburg-Essen, Essen, Germany
,
Theodoros Kontakiotis1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Kosmas Tsakiridis3 Thoracic Surgery Department, “Saint Luke” Private Hospital, Panorama, Thessaloniki, Greece
,
Konstantinos Porpodis1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Dimitrios Latsios1 Pulmonary Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Olga Chatzizisi4 Immunology Department, “G Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
,
Ilias Karapantzos5 Ear, Nose and Throat Department, “Saint Luke” Private Hospital, Panorama, Thessaloniki, Greece
,
Qiang Li6 Respiratory Diseases Department, Shanghai hospital, Second Military Medical University, Shanghai, People’s Republic of China
&
Georgios Kyriazis2 Department of Interventional Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital, University Duisburg-Essen, Essen, Germany
 show all
Pages 611-617 | Published online: 23 Jul 2013

Figures & data

Table 1 Patients’ characteristics

Figure 1 Survival in days for all stages.

Notes: group A, chemotherapy alone; group B, chemotherapy and IFN-α; group C, chemotherapy and IFN-γ; group D, chemotherapy and both IFN-α and IFN-γ.
Abbreviations: IFN-α, interferon alpha; IFN-γ, interferon gamma.
Figure 1 Survival in days for all stages.

Table 2 Response rates

Table 3 Median survival in months

Table 4 Mean values of fluctuation of immune markers

Figure 2 Survival in days for limited disease.

Notes: group A, chemotherapy alone; group B, chemotherapy and IFN-α; group C, chemotherapy and IFN-γ; group D, chemotherapy and both IFN-α and IFN-γ.
Abbreviations: LD SCLC, limited disease small cell lung cancer; IFN-α, interferon alpha; IFN-γ, interferon gamma.
Figure 2 Survival in days for limited disease.

Figure 3 Survival in days for extensive disease.

Notes: group A, chemotherapy alone; group B, chemotherapy and IFN-α; group C, chemotherapy and IFN-γ; group D, chemotherapy and both IFN-α and IFN-γ.
Abbreviations: ED SCLC, extensive disease small cell lung cancer; IFN-α, interferon alpha; IFN-γ, interferon gamma.
Figure 3 Survival in days for extensive disease.

Table 5 Toxicity: patients who suffered at least one single event

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.